Center for Research on Complex Generics (U18) Clinical Trials Optional
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you run a research institution with capacity in pharmaceutical sciences and clinical trial infrastructure, FDA is funding centers to tackle generic drug complexity—a high-impact, underserved research area.
Report stale or inaccurate summary
What this is
This is an FDA-sponsored cooperative agreement (U18) focused on establishing research centers that investigate complex generic drug formulations and conduct associated clinical trials. The funding supports institutional capacity-building around generic drug development, which is critical for FDA's mission to expand access to affordable medications. Eligibility details and award amounts are not specified in the source material, making preliminary assessment difficult.
Who can apply
Eligibility criteria are not specified in the provided source material. Typically, FDA U18 awards go to research institutions, universities, and established organizations with clinical trial and pharmaceutical research capacity; solo founders and early-stage startups are unlikely to qualify.
Topics: generic drugs · clinical trials · drug formulation · fda research · pharmaceutical development
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.